This Ambirix market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed during the historical period can be attributed to the increasing prevalence of related medical conditions, a higher demand for home care solutions, expanded healthcare infrastructure investments, greater awareness of preventive care, and a rising geriatric population.
The projected growth during the forecast period is driven by a growing demand for personalized healthcare solutions, the expansion of telemedicine and remote patient monitoring, increasing healthcare expenditures, a stronger focus on patient-centric care, and regulatory approvals for new treatment options. Key trends during the forecast period include the development of innovative healthcare products, advancements in medical technology, strategic partnerships and collaborations in the healthcare industry, increased investments in research and development, and the growth of home care services.
The growing prevalence of hepatitis infections is anticipated to drive the expansion of the ambirix market in the future. Hepatitis refers to liver inflammation, which results in liver cell damage and impaired liver function. Hepatitis, especially types A and B, continues to be a global health challenge due to rising infection rates driven by factors such as poor sanitation, low vaccination coverage, and increased population mobility. Ambirix is a combination vaccine designed to protect against hepatitis A and B infections in children aged 1 to 15 years, offering long-lasting immunity with a two-dose regimen. It is especially recommended in areas with moderate to high infection risks. For example, in April 2024, a report from the Centers for Disease Control and Prevention (CDC) indicated that in 2022, there were 2,126 new cases of acute hepatitis B and an estimated 13,800 acute HBV infections. Additionally, 16,729 new cases of chronic hepatitis B were reported, along with 1,797 hepatitis B-related deaths. Consequently, the increasing incidence of hepatitis infections is fueling the growth of the ambirix market.
Rising awareness of pediatric vaccination is expected to further accelerate the growth of the ambirix market. Pediatric vaccination is the immunization of children to protect them from infectious diseases, which is crucial for reducing the global burden of preventable illnesses. The awareness of pediatric vaccination is growing due to public health campaigns, school-based immunization programs, and efforts by governments and healthcare organizations to promote the benefits of vaccination. Vaccines such as Ambirix, which target hepatitis A and B, are vital for protecting children’s health and improving vaccination coverage in regions with traditionally low immunization rates. For example, in July 2024, a report by the World Health Organization (WHO) highlighted that global coverage of the first dose of the HPV vaccine for girls increased to 27% in 2023, up from 20% in 2022, driven by new introductions in several countries and the adoption of a one-dose schedule. As a result, growing awareness of pediatric vaccination will contribute to the expansion of the ambirix market.
The rising healthcare expenditure is expected to boost the growth of the ambirix market. Healthcare expenditure refers to the allocation of financial resources toward health services, including vaccination programs and access to combined hepatitis A and B vaccines. This expenditure encompasses spending on medical services, goods, and public health initiatives aimed at maintaining and improving health. Ambirix plays a role in healthcare expenditure by reducing the long-term treatment costs associated with hepatitis A and B through effective prevention. Its use supports cost-efficient public health strategies. For instance, a report published by the Office for National Statistics in May 2024 indicated that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Furthermore, total long-term health and social care expenditure rose by 2.8% in real terms in 2022. As a result, the increase in healthcare spending is expected to drive the growth of the ambirix market.
The key company operating in the ambirix market is GSK plc.
North America was the largest region in the ambirix market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ambirix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ambirix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Ambirix is a combination vaccine designed to protect against both hepatitis A and hepatitis B. It contains an inactivated hepatitis A virus and a purified hepatitis B surface antigen, which work together to stimulate the immune system. This vaccine is primarily recommended for individuals between the ages of 1 and 15 years, administered in two doses over a six-month period. It offers long-term protection, significantly lowering the risk of severe liver diseases associated with these viruses.
The primary uses of ambirix are for preventing hepatitis A and hepatitis B. Hepatitis A is a contagious liver infection caused by the hepatitis A virus (HAV). The vaccine is distributed through hospitals, pharmacies, and public health programs, and is intended for use by both pediatric and geriatric populations.
The ambirix market research report is one of a series of new reports that provides ambirix market statistics, including ambirix industry global market size, regional shares, competitors with a ambirix market share, detailed ambirix market segments, market trends and opportunities, and any further data you may need to thrive in the ambirix industry. This ambirix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ambirix market consists of sales of single-pack doses, multi-pack doses of pre-filled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed during the historical period can be attributed to the increasing prevalence of related medical conditions, a higher demand for home care solutions, expanded healthcare infrastructure investments, greater awareness of preventive care, and a rising geriatric population.
The projected growth during the forecast period is driven by a growing demand for personalized healthcare solutions, the expansion of telemedicine and remote patient monitoring, increasing healthcare expenditures, a stronger focus on patient-centric care, and regulatory approvals for new treatment options. Key trends during the forecast period include the development of innovative healthcare products, advancements in medical technology, strategic partnerships and collaborations in the healthcare industry, increased investments in research and development, and the growth of home care services.
The growing prevalence of hepatitis infections is anticipated to drive the expansion of the ambirix market in the future. Hepatitis refers to liver inflammation, which results in liver cell damage and impaired liver function. Hepatitis, especially types A and B, continues to be a global health challenge due to rising infection rates driven by factors such as poor sanitation, low vaccination coverage, and increased population mobility. Ambirix is a combination vaccine designed to protect against hepatitis A and B infections in children aged 1 to 15 years, offering long-lasting immunity with a two-dose regimen. It is especially recommended in areas with moderate to high infection risks. For example, in April 2024, a report from the Centers for Disease Control and Prevention (CDC) indicated that in 2022, there were 2,126 new cases of acute hepatitis B and an estimated 13,800 acute HBV infections. Additionally, 16,729 new cases of chronic hepatitis B were reported, along with 1,797 hepatitis B-related deaths. Consequently, the increasing incidence of hepatitis infections is fueling the growth of the ambirix market.
Rising awareness of pediatric vaccination is expected to further accelerate the growth of the ambirix market. Pediatric vaccination is the immunization of children to protect them from infectious diseases, which is crucial for reducing the global burden of preventable illnesses. The awareness of pediatric vaccination is growing due to public health campaigns, school-based immunization programs, and efforts by governments and healthcare organizations to promote the benefits of vaccination. Vaccines such as Ambirix, which target hepatitis A and B, are vital for protecting children’s health and improving vaccination coverage in regions with traditionally low immunization rates. For example, in July 2024, a report by the World Health Organization (WHO) highlighted that global coverage of the first dose of the HPV vaccine for girls increased to 27% in 2023, up from 20% in 2022, driven by new introductions in several countries and the adoption of a one-dose schedule. As a result, growing awareness of pediatric vaccination will contribute to the expansion of the ambirix market.
The rising healthcare expenditure is expected to boost the growth of the ambirix market. Healthcare expenditure refers to the allocation of financial resources toward health services, including vaccination programs and access to combined hepatitis A and B vaccines. This expenditure encompasses spending on medical services, goods, and public health initiatives aimed at maintaining and improving health. Ambirix plays a role in healthcare expenditure by reducing the long-term treatment costs associated with hepatitis A and B through effective prevention. Its use supports cost-efficient public health strategies. For instance, a report published by the Office for National Statistics in May 2024 indicated that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Furthermore, total long-term health and social care expenditure rose by 2.8% in real terms in 2022. As a result, the increase in healthcare spending is expected to drive the growth of the ambirix market.
The key company operating in the ambirix market is GSK plc.
North America was the largest region in the ambirix market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ambirix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ambirix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Ambirix is a combination vaccine designed to protect against both hepatitis A and hepatitis B. It contains an inactivated hepatitis A virus and a purified hepatitis B surface antigen, which work together to stimulate the immune system. This vaccine is primarily recommended for individuals between the ages of 1 and 15 years, administered in two doses over a six-month period. It offers long-term protection, significantly lowering the risk of severe liver diseases associated with these viruses.
The primary uses of ambirix are for preventing hepatitis A and hepatitis B. Hepatitis A is a contagious liver infection caused by the hepatitis A virus (HAV). The vaccine is distributed through hospitals, pharmacies, and public health programs, and is intended for use by both pediatric and geriatric populations.
The ambirix market research report is one of a series of new reports that provides ambirix market statistics, including ambirix industry global market size, regional shares, competitors with a ambirix market share, detailed ambirix market segments, market trends and opportunities, and any further data you may need to thrive in the ambirix industry. This ambirix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ambirix market consists of sales of single-pack doses, multi-pack doses of pre-filled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Ambirix Market Characteristics4. Ambirix Market Trends and Strategies5. Ambirix Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Ambirix Pricing Analysis & Forecasts30. Global Ambirix Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Ambirix Market32. Recent Developments in the Ambirix Market
3. Ambirix Market Biologic Drug Characteristics
6. Global Ambirix Growth Analysis and Strategic Analysis Framework
8. Ambirix Market Segmentation
9. Global Ambirix Epidemiology of Clinical Indications
10. Ambirix Market Regional and Country Analysis
11. Asia-Pacific Ambirix Market
12. China Ambirix Market
13. India Ambirix Market
14. Japan Ambirix Market
15. Australia Ambirix Market
16. South Korea Ambirix Market
17. Western Europe Ambirix Market
18. UK Ambirix Market
19. Germany Ambirix Market
20. France Ambirix Market
21. Eastern Europe Ambirix Market
22. North America Ambirix Market
23. USA Ambirix Market
24. Canada Ambirix Market
25. South America Ambirix Market
26. Middle East Ambirix Market
27. Africa Ambirix Market
28. Ambirix Market Competitive Landscape and Company Profiles
29. Global Ambirix Market Pipeline Analysis
33. Ambirix Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Ambirix Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on ambirix market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ambirix? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ambirix market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Hepatitis a; Hepatitis B2) by Distribution Channel: Hospitals; Pharmacies; Public Health Programs
3) by End User: Pediatric; Geriatric
Key Companies Mentioned: GSK plc
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- GSK plc
